Bevacizumab dose adjustment to improve clinical outcomes of glioblastoma

BACKGROUND: Glioblastoma (GBM) is one of the most aggressive and vascularized brain tumors in adults, with a median survival of 20.9 months. In newly diagnosed and recurrent GBM, bevacizumab demonstrated an increase in progression-free survival, but not in overall survival. METHODS: We conducted an...

Descripción completa

Detalles Bibliográficos
Autores principales: García-Romero, N., Palacín-Aliana, I., Madurga, R., Carrión-Navarro, J., Esteban-Rubio, S., Jiménez, B., Collazo, A., Pérez-Rodríguez, F., Ortiz de Mendivil, A., Fernández-Carballal, C., García-Duque, S., Diamantopoulos-Fernández, J., Belda-Iniesta, C., Prat-Acín, R., Sánchez-Gómez, P., Calvo, E., Ayuso-Sacido, A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310142/
https://www.ncbi.nlm.nih.gov/pubmed/32564774
http://dx.doi.org/10.1186/s12916-020-01610-0

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7310142/
https://www.ncbi.nlm.nih.gov/pubmed/32564774
http://dx.doi.org/10.1186/s12916-020-01610-0

Ejemplares similares